Titre :

Crohn''s disease and autologous hemapoietic cell transplantation: guidelines from the francophone society of bone marrow transplantation and cellular therapy (sfgm-tc)

Auteur(s) :

Puyade, Mathieu [Auteur]
Treton, Xavier [Auteur]
Alric, Laurent [Auteur]
Badoglio, Manuela [Auteur]
Castilla Llorente, Cristina [Auteur]
Fotsing, Ginette [Auteur]
Marjanovic, Zora [Auteur]
Rovira, Montserrat [Auteur]
Terriou, Louis [Auteur]
Torregrosa Diaz Jose, Miguel [Auteur]
Tran-Minh, My-Linh [Auteur]
Allez, Matthieu [Auteur]
Pugnet, Gregory [Auteur]
Laharie, David [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Farge, Dominique [Auteur]

Titre de la revue :

Bulletin du cancer

Nom court de la revue :

Bull Cancer

Date de publication :

2020-10-13

ISSN :

1769-6917

Mot(s)-clé(s) :

Immunosuppression
Conditionning regimen
Post autologous stem cell transplantation follow-up
Supportive Care
Intensive
Crohn's disease
Autologous hematopoietic cell transplantation
Mobilization of hematopoietic cell

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Crohn's Disease (CD) is an auto-inflammatory disease, which may involve the entire gastro-intestinal tract. CD is diagnosed on several clinical, biological, endoscopic and histological criteria. First line therapy is based ...
Lire la suite >Crohn's Disease (CD) is an auto-inflammatory disease, which may involve the entire gastro-intestinal tract. CD is diagnosed on several clinical, biological, endoscopic and histological criteria. First line therapy is based on oral or iv steroids. In case of steroids dependence or resistance, several types of immunosuppressive or immunomodulating therapies are available: classical antimetabolites (thiopurines or methotrexate) or monoclonal antibodies against TNFα, against interleukin 12/23 or against integrin. Nonetheless, Crohn's disease may remain active despite the use of several lines of therapy. In such cases, autologous hematopoietic cell transplantation (AHCT) is an effective therapeutic option in highly selected CD patients with specific criteria. The MATHEC-SFGM-TC Good Clinical Practice Guidelines (GCPG) were developed by a multidisciplinary group of experts including gastroenterologists, hematologists and members of the reference center for stem cell therapy in auto-immune diseases (MATHEC), including members of the French groupe d'étude thérapeutique des affections inflammatoires du tube digestif(GETAID) under the auspices of the French speaking Society of bone marrow transplantation and cellular therapy (SFGM-TC). The aim of the present guidelines is to define the eligibility criteria for CD patients when candidates to AHCT, the procedures for mobilization of hematopoietic stem cell (HSC), conditioning regimen and standardized follow-up after AHCT including monitoring of gastroenterological treatments during AHCT and thereafter throughout all follow-up.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:48:48Z